Ian Elliott Krop, MD, PhD, is the Chief Clinical Research Officer and Associate Cancer Center Director for Clinical Research at Yale Cancer Center in New Haven, CT. He also serves as the Chief Scientific Officer for the Translational Breast Cancer Research Consortium (TBCRC).

Dr. Krop is a translational investigator focused on the development of novel molecularly targeted therapies and immunotherapies for breast cancer and elucidating the mechanisms of resistance to these treatments. The majority of his effort is concentrated in the area of HER2+ breast cancer. He was a leader in the development of the antibody-drug conjugates trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan.

Dr. Krop is a graduate of Johns Hopkins University and Johns Hopkins University School of Medicine. He trained at Johns Hopkins Hospital, Dana-Farber Cancer Institute, Harvard